- A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. Hainsworth, J.D., Cebotaru, C.L., Kanarev, V., Ciuleanu, T.E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., Tzekova, V. J. Thorac. Oncol (2010)